CervoMed Statistics
Total Valuation
CervoMed has a market cap or net worth of $28.15 million. The enterprise value is $15.22 million.
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CervoMed has 9.26 million shares outstanding. The number of shares has increased by 5.45% in one year.
| Current Share Class | 9.26M |
| Shares Outstanding | 9.26M |
| Shares Change (YoY) | +5.45% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 32.04% |
| Owned by Institutions (%) | 19.16% |
| Float | 6.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.47 |
| Forward PS | n/a |
| PB Ratio | 2.65 |
| P/TBV Ratio | 2.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36
| Current Ratio | 3.36 |
| Quick Ratio | 2.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -132.76% and return on invested capital (ROIC) is -85.92%.
| Return on Equity (ROE) | -132.76% |
| Return on Assets (ROA) | -72.41% |
| Return on Invested Capital (ROIC) | -85.92% |
| Return on Capital Employed (ROCE) | -292.99% |
| Weighted Average Cost of Capital (WACC) | -20.34% |
| Revenue Per Employee | $139,268 |
| Profits Per Employee | -$2.00M |
| Employee Count | 15 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.11% in the last 52 weeks. The beta is -4.47, so CervoMed's price volatility has been lower than the market average.
| Beta (5Y) | -4.47 |
| 52-Week Price Change | -64.11% |
| 50-Day Moving Average | 3.78 |
| 200-Day Moving Average | 6.53 |
| Relative Strength Index (RSI) | 33.54 |
| Average Volume (20 Days) | 66,767 |
Short Selling Information
The latest short interest is 281,907, so 3.04% of the outstanding shares have been sold short.
| Short Interest | 281,907 |
| Short Previous Month | 274,262 |
| Short % of Shares Out | 3.04% |
| Short % of Float | 4.48% |
| Short Ratio (days to cover) | 7.52 |
Income Statement
In the last 12 months, CervoMed had revenue of $2.09 million and -$30.04 million in losses. Loss per share was -$3.27.
| Revenue | 2.09M |
| Gross Profit | -20.02M |
| Operating Income | -31.10M |
| Pretax Income | -30.04M |
| Net Income | -30.04M |
| EBITDA | n/a |
| EBIT | -31.10M |
| Loss Per Share | -$3.27 |
Full Income StatementBalance Sheet
The company has $12.92 million in cash and n/a in debt, with a net cash position of $12.92 million or $1.40 per share.
| Cash & Cash Equivalents | 12.92M |
| Total Debt | n/a |
| Net Cash | 12.92M |
| Net Cash Per Share | $1.40 |
| Equity (Book Value) | 10.62M |
| Book Value Per Share | 1.15 |
| Working Capital | 10.62M |
Full Balance SheetCash Flow
| Operating Cash Flow | -27.57M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,488.86% |
| Pretax Margin | -1,437.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CervoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.45% |
| Shareholder Yield | -5.45% |
| Earnings Yield | -106.71% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CervoMed is $20.33, which is 568.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.33 |
| Price Target Difference | 568.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 119.01% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CervoMed has an Altman Z-Score of -6.42 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.42 |
| Piotroski F-Score | 1 |
